Phase 2 N=16 N-acetylcysteine and NMDA Antagonist Interactions
Cognitive Dysfunction
Primary: Target P300 — 2.5; 3.2; 5.2; 3.4 microvolts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 NMDA Receptors in Motor Learning in Humans
Stroke
Primary: Grip Strength of Affected Hand — 3.95; 5.72; 4.90; 8.44 Newton
N/A N=35 Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans
Healthy
Primary: Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours — 0.5; 0.0 units on a scale
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
Phase 3 N=104 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Wisconsin Card Sorting Test (WCST) — 38.43; 35.79; 43.14; 39.57 percentage of correct responses
Phase 2 N=20 Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Alcoholism · Schizophrenia
Primary: Self Reported Weekly Alcohol Consumption — 23.4; 19.6; 15.7; 10.0 percentage of days
Phase 2 N=45 D-serine Augmentation of Neuroplasticity
Schizophrenia · Schizo Affective Disorder
Primary: Plasticity Improvement (Change in Tone Matching Threshold) — 13.9; 5.3; 11; -0.05 log ratio
Phase 4 N=36 Biomarker Study of Acamprosate in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Anterior Cingulate Cortex - Choline — 1.64; 1.54; 1.46; 1.58 mM
Phase 1 N=5 Antidepressant Effects of NR2B in Major Depression
Major Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 22.519; 23.633 Score on a scale — p=.272
Phase 2 N=8 Glutamatergic Modulation of Cocaine-related Deficits
Cocaine Dependence
Primary: Change in Cue Reactivity — 126; 18; 16 units on a scale (0-200), high is worse
N/A N=30 The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
Parkinson's Disease With Dementia
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks. — 71.6; 66.7; 67.9; 65.2 Scores on a scale
Phase 4 N=40 Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Psychoses, Substance-Induced
Primary: Brief Psychiatric Ratings Scale (BPRS) Positive Symptom Subscale Score — 0.00; 0.00; 1.40; 1.00 Scale of 0-6
Phase 4 N=42 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
Schizophrenia · Schizo Affective Disorder · Schizoaffective Disorder
Primary: Prepulse Inhibition (PPI) — 32.45; 26.85; 14.11; 11.78 % inhibition of startle
Phase 2 N=16 Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid Dependence
Primary: Successful Naltrexone Initiation — 11 Participants
Phase 3 N=17 The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
Alzheimer Disease
Primary: NAA/Cr Ratio — 1.47; 1.38; 1.62; 1.41 Ratio
Phase 4 N=17 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Alzheimer's Disease
Primary: N-acetylaspartate — 1.35; 1.86; 1.58; 1.26 NAA/creatine Ratio
N/A N=79 PET Imaging of mGLuR5 With Drug Challenge
Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Primary: Change in Glutamate Levels at Baseline and After Ketamine Administration as Confirmed by Positron Emission Tomography (PET) Imaging — 19; 14; 31; 14 percentage reduction
N/A N=12 Mechanisms of Insulin Facilitation of Memory
Memory Disorders
Primary: Cerebral Glutamate Concentration — 1.34; 1.34 ratio
Phase 3 N=8 Glycine vs Placebo for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale
Phase 4 N=8 NMDA Antagonists in Bipolar Depression
Bipolar Disorder
Primary: Hamilton Depression Rating Scale (HAM-D) — 9.5 units on a scale (final score) — p=<0.001
Phase 4 N=59 Biomarker Assessment of Glutamatergic Target Engagement
Healthy Controls
Primary: Glutamate + Glutamine (Glx) Response — 0.015; 0.007 Glx over creatinine ratio
Phase 2 N=175 Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Mild Cognitive Impairment
Primary: 15-Item Word List Delayed Recall — -0.3; -0.5 units on a scale - change from baseline — p=<.05
Phase 4 N=72 Memantine and Cognitive Dysfunction in Bipolar Disorder
Bipolar Disorder
Primary: California Verbal Learning Test (CVLT) at Week 12 — 11.88; 11.55; 11.63; 11.73 correct items
Phase 2 N=3 Histamine Glutamate Antagonism in Stroke
Acute Cerebrovascular Accident · Cerebral Edema
Primary: Modified Rankin Score
Early Phase 1 N=2 Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
Schizophrenia · Bipolar Disorder
Primary: Positive and Negative Symptom Scores — 14.5; 11; 14.5; 14 units on a scale
Phase 3 N=17 Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
Obsessive-Compulsive Disorder · Generalized Anxiety Disorder
Primary: Psychometric Scores — 16.4; 18.86; 27.6; 24.3 units on a scale
Phase 2 N=2 Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
Schizo-affective Disorder · Bipolar Disorder
Primary: Positive and Negative Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks During Intervention 1 (Glycine or Placebo), Intervention 2 (Glycine or Placebo)…
Phase 2 N=302 A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.37; -14.40; -13.18 units on a scale — p=0.630
Phase 4 N=21 Network-Level Effects of Nitrous Oxide in the Human Brain
Healthy
Primary: Functional Connectivity During Nitrous Oxide — 0.1123; 0.0358; 0.1492; 0.0394 Fisher's r transformed z score — p=0.001
Phase 2 N=81 Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2
Cocaine-Related Disorders
Primary: Weekly Cocaine Use — 1.1; 1.3 days